Thompson Siegel & Walmsley LLC Has $13.73 Million Stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Thompson Siegel & Walmsley LLC increased its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 17.6% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 230,159 shares of the specialty pharmaceutical company’s stock after acquiring an additional 34,416 shares during the period. Thompson Siegel & Walmsley LLC owned about 1.09% of ANI Pharmaceuticals worth $13,731,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Innealta Capital LLC bought a new stake in shares of ANI Pharmaceuticals during the 2nd quarter valued at $65,000. Ridgewood Investments LLC bought a new stake in shares of ANI Pharmaceuticals in the second quarter worth $85,000. SG Americas Securities LLC bought a new stake in ANI Pharmaceuticals during the 1st quarter worth about $106,000. O Shaughnessy Asset Management LLC acquired a new position in ANI Pharmaceuticals during the first quarter valued at approximately $218,000. Finally, XTX Topco Ltd acquired a new stake in shares of ANI Pharmaceuticals in the 2nd quarter valued at approximately $207,000. 76.05% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. Piper Sandler started coverage on shares of ANI Pharmaceuticals in a research report on Friday, October 11th. They set an “overweight” rating and a $68.00 price target on the stock. HC Wainwright restated a “buy” rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a research note on Monday, November 11th. StockNews.com downgraded ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, September 7th. Truist Financial raised their price target on ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a “hold” rating in a report on Tuesday, October 22nd. Finally, Raymond James upped their price objective on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an “outperform” rating in a report on Wednesday, September 18th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, ANI Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $77.33.

ANI Pharmaceuticals Trading Down 1.1 %

NASDAQ ANIP opened at $55.10 on Thursday. ANI Pharmaceuticals, Inc. has a 12-month low of $48.20 and a 12-month high of $70.81. The firm has a 50-day moving average price of $58.35 and a two-hundred day moving average price of $61.07. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings data on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.09 by $0.25. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. The firm had revenue of $148.30 million for the quarter, compared to the consensus estimate of $144.37 million. During the same period in the prior year, the company posted $1.05 earnings per share. The business’s revenue for the quarter was up 12.5% on a year-over-year basis. On average, equities analysts predict that ANI Pharmaceuticals, Inc. will post 3.87 earnings per share for the current year.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.